Viatris Inc. (VTRS)
VTRS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$17.25
-1.65% on the day
Market cap
$19.8B
Large cap
Revenue · 2025
$14.3B
-3.0% on 2024
Net income · 2025
Net income not in SEC XBRL data
0.0% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | VTRS on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001792044 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $14.3B |
| Net income | Not in SEC XBRL data |
| Operating income | -$2.7B |
| Net margin | 0.0% |
| Operating margin | -18.6% |
| Revenue growth | -3.0% |
| Cash | $1.3B |
| Total assets | $37.2B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.4× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-06-15 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-08-06 |
| Latest current report | 8-K | 2026-10-08 |
| Latest proxy | DEFA14A | 2026-04-02 |
Source: SEC EDGAR submissions feed, 541 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -0.3% |
| 1 month | +4.7% |
| 3 months | +0.6% |
| Year to date | +40.1% |
| 1 year | +76.9% |
| From 52-week high | -4.5% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| INSM | Insmed Incorporated | $96.79 | -1.80% | $21.1B |
| GMAB | Genmab A/S ADS | $36.57 | -2.14% | $22.8B |
| UTHR | United Therapeutics Corporation | $543.40 | -1.22% | $23.3B |
| ROIV | Roivant Sciences Ltd. Common Shares | $33.35 | -3.58% | $24.1B |
| ASND | Ascendis Pharma A/S Ordinary Share | $223.21 | -1.67% | $14.7B |
| JAZZ | Jazz Pharmaceuticals plc Common Stock (Ireland) | $210.39 | -2.93% | $13.7B |
| ALNY | Alnylam Pharmaceuticals Inc. | $223.82 | -1.41% | $29.9B |
| ZTS | Zoetis Inc. | $74.30 | -1.78% | $30.7B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier